SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Swarna Maseneni, Massimiliano Donzelli, Anne Barbara Taegtmeyer, Karin Brecht, Stephan Krähenbühl, Toxicity of clopidogrel and ticlopidine on human myeloid progenitor cells: Importance of metabolites, Toxicology, 2012, 299, 2-3, 139

    CrossRef

  2. 2
    Shinji Shimizu, Ryo Atsumi, Tsunenori Nakazawa, Takashi Izumi, Kenichi Sudo, Osamu Okazaki, Hideo Saji, Ticlopidine-induced hepatotoxicity in a GSH-depleted rat model, Archives of Toxicology, 2011, 85, 4, 347

    CrossRef

  3. 3
    Natasa Colovic, Ljiljana Bumbasirevic, Vuk Palibrk, Ana Vidovic, Milica Colovic, Neuroborreliosis in patient with aplastic anaemia secondary to therapy with ticlopidine, Srpski arhiv za celokupno lekarstvo, 2010, 138, 9-10, 632

    CrossRef

  4. 4
    Ji Yeon Lee, Eun Bum Park, Jae Hong Ahn, Sang-jun Suh, Young Kul Jung, Ji Hoon Kim, Bong Kyung Shin, Jin Hyuk Yang, Jong Eun Yeon, Kwan Soo Byun, A case of ticlopidine induced acute cholestatic hepatitis and pure red cell aplasia, The Korean Journal of Hepatology, 2008, 14, 1, 102

    CrossRef

  5. 5
    Edeltraut Garbe, Non-chemotherapy drug-induced agranulocytosis, Expert Opinion on Drug Safety, 2007, 6, 3, 323

    CrossRef

  6. 6
    Igor Mosyagin, Ingolf Cascorbi, Rainer Schaub, Timo Kr??ger, Michael Dettling, Drug-Induced Agranulocytosis, Journal of Clinical Psychopharmacology, 2005, 25, 5, 435

    CrossRef

  7. 7
    Petcharat Dusitanond, Graeme J Hankey, Ticlopidine, Journal of Drug Evaluation, 2004, 2, 6, 163

    CrossRef

  8. 8
    Nobuo Waguri, Masaru Yamamoto, Intrahepatic cholestasis and pure red cell aplasia associated with ticlopidine, European Journal of Internal Medicine, 2003, 14, 3, 192

    CrossRef

  9. 9
    Henry J. Pieniaszek, Sherwin K. B. Sy, William Ebling, Michael J. Fossler, Valerie A. Cain, John T. Mondick, Su Ma, David M. Kornhauser, Safety, Tolerability, Pharmacokinetics, and Time Course of Pharmacologic Response of the Active Metabolite of Roxifiban, XV459, a Glycoprotein IIb/IIIa Antagonist, following Oral Administration in Healthy Volunteers, The Journal of Clinical Pharmacology, 2002, 42, 7
  10. 10
    A. Symeonidis, A. Kouraklis-Symeonidis, U. Seimeni, A. Galani, N. Giannakoulas, E. Fragopanagou, M. Tiniakou, P. Matsouka, N. Zoumbos, Ticlopidine-induced aplastic anemia: Two new case reports, review, and meta-analysis of 55 additional cases, American Journal of Hematology, 2002, 71, 1
  11. 11
    Yolanda Braun-Moscovici, Daniel Schapira, Alexandra Balbir-Gurman, Ronit Sevilia, A. Menachem Nahir, Ticlopidine-Induced Lupus, JCR: Journal of Clinical Rheumatology, 2001, 7, 2, 102

    CrossRef

  12. 12
    M. Gallerani, R. Manfredini, P. Doneg??, F. Lanza, M. Da Busti, G. B. Vigna, R. Fellin, Adverse Haematological Effects of Ticlopidine, Clinical Drug Investigation, 2000, 19, 3, 231

    CrossRef

  13. 13
    A. Taher, Z. Ammash, B. Dabajah, A. Nasrallah, F. H. Mourad, Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: Case report and literature review, American Journal of Hematology, 2000, 63, 2
  14. 14
    Vinod A. Pullarkat, Hyan Rho, Joyce L. Murata-Collins, Howard A. Liebman, Ticlopidine-induced aplastic anemia: Development of chromosomal abnormalities and response to immunosuppressive therapy, American Journal of Hematology, 2000, 63, 3
  15. 15
    Nishit B. Modi, William Novotny, James D. Reimann, Christopher P. Cannon, Eugene Braunwauld, Pharmacokinetics and Pharmacodynamics of Sibrafiban, an Orally Administered IIb/IIIa Antagonist, in Patients with Acute Coronary Syndrome, The Journal of Clinical Pharmacology, 1999, 39, 7
  16. 16
    Cengiz Ceylan, Önder Kirimli, Mesut Akarsu, Bülent Ündar, Sema Güneri, Early ticlopidine-induced hepatic dysfunction, dermatitis and irreversible aplastic anemia after coronary artery stenting, American Journal of Hematology, 1998, 59, 3
  17. 17
    Nishit B. Modi, Yvonne S. Lin, Theresa Reynolds, Allison Shaheen, Brian J. Christian, Pharmacokinetics and Pharmacodynamics of Sibrafiban (Ro 48-3657), an Orally Active IIb/IIIa Antagonist, Administered Alone or in Combination with Heparin, Aspirin, and Recombinant Tissue-Type Plasminogen Activator in Beagles, Journal of Cardiovascular Pharmacology, 1998, 32, 3, 397

    CrossRef

  18. 18
    JP de Jaureguiberry, M Galzin, P Talard, S Marlier, S Durupt, C Bouchiat, GV Dussarat, D Jaubert, Aplasie médullaire associée à la ticlopidine, La Revue de Médecine Interne, 1996, 17, 12, 1032

    CrossRef

  19. 19
    Peter Jacobs, Bone marrow failure: Pathophysiology and management, Disease-a-Month, 1995, 41, 4, 206

    CrossRef

  20. 20
    Kazutoshi Ono, Yasuhiro Imazono, Tadashi Misawa, Junji Nishimura, Hajime Nawata, Natural killing activity is associated with progression of gastric cancer, Journal of Clinical Immunology, 1995, 15, 4, 210

    CrossRef

  21. 21
    K. Arribalzaga, J. García-Suárez, M. López-Rubio, I. Krsnik, M. A. Calero, J. F. Del Campo, Sustained granulocyte recovery after G-CSF in a patient with ticlopidine-induced severe aplastic anemia, American Journal of Hematology, 1995, 50, 4
  22. 22
    J. N. Rodriguez, A. Fernandez-Jurado, J. C. Dieguez, A. Amian, D. Prados, Ticlopidine and severe aplastic anemia, American Journal of Hematology, 1994, 47, 4
  23. 23
    Rodolfo Mataix, Emilio Ojeda, Maria Carmen Perez, Santiago Jimenez, TICLOPIDINE AND SEVERE APLASTIC ANAEMIA, British Journal of Haematology, 1992, 80, 1
  24. 24
    Matthew J. Hutzler, Matthew A. Cerny, Bioactivation II: Phase I (Non-P450), Encyclopedia of Drug Metabolism and Interactions,